JP2011524903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524903A5 JP2011524903A5 JP2011514598A JP2011514598A JP2011524903A5 JP 2011524903 A5 JP2011524903 A5 JP 2011524903A5 JP 2011514598 A JP2011514598 A JP 2011514598A JP 2011514598 A JP2011514598 A JP 2011514598A JP 2011524903 A5 JP2011524903 A5 JP 2011524903A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- present
- compound
- weight
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 26
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 239000000203 mixture Substances 0.000 claims 14
- 239000000945 filler Substances 0.000 claims 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 8
- 239000001509 sodium citrate Substances 0.000 claims 8
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 8
- 239000000314 lubricant Substances 0.000 claims 7
- 239000004067 bulking agent Substances 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 239000004471 Glycine Substances 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000006172 buffering agent Substances 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 239000008176 lyophilized powder Substances 0.000 claims 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000001931 aliphatic group Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000006574 non-aromatic ring group Chemical group 0.000 claims 3
- 229920003109 sodium starch glycolate Polymers 0.000 claims 3
- 229940079832 sodium starch glycolate Drugs 0.000 claims 3
- 239000008109 sodium starch glycolate Substances 0.000 claims 3
- 239000000454 talc Substances 0.000 claims 3
- 229910052623 talc Inorganic materials 0.000 claims 3
- 239000008181 tonicity modifier Substances 0.000 claims 3
- -1 2,5-dichlorophenyl Chemical group 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004108 freeze drying Methods 0.000 claims 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000003021 water soluble solvent Substances 0.000 claims 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 229920000881 Modified starch Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims 1
- 239000008116 calcium stearate Substances 0.000 claims 1
- 235000013539 calcium stearate Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229940049654 glyceryl behenate Drugs 0.000 claims 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 235000019814 powdered cellulose Nutrition 0.000 claims 1
- 229920003124 powdered cellulose Polymers 0.000 claims 1
- 229920003133 pregelled starch Polymers 0.000 claims 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 229940032147 starch Drugs 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 239000008215 water for injection Substances 0.000 claims 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims 1
- 0 CC(C)(C(C(*)NC(C)(C)P)=O)NC(*)C(NCBOC(CC(O)=O)(CC(O)=O)C(O)=O)=O Chemical compound CC(C)(C(C(*)NC(C)(C)P)=O)NC(*)C(NCBOC(CC(O)=O)(CC(O)=O)C(O)=O)=O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13224408P | 2008-06-17 | 2008-06-17 | |
| US61/132,244 | 2008-06-17 | ||
| US21149909P | 2009-03-31 | 2009-03-31 | |
| US61/211,499 | 2009-03-31 | ||
| PCT/US2009/003602 WO2009154737A1 (en) | 2008-06-17 | 2009-06-16 | Boronate ester compounds and pharmaceutical compositions thereof |
Related Child Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103397A Division JP5926319B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103398A Division JP2014169317A (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103395A Division JP6010066B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103396A Division JP6110813B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524903A JP2011524903A (ja) | 2011-09-08 |
| JP2011524903A5 true JP2011524903A5 (enExample) | 2012-08-02 |
| JP5566380B2 JP5566380B2 (ja) | 2014-08-06 |
Family
ID=41061278
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011514598A Active JP5566380B2 (ja) | 2008-06-17 | 2009-06-16 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103398A Withdrawn JP2014169317A (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103396A Active JP6110813B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103395A Active JP6010066B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103397A Active JP5926319B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2017128843A Withdrawn JP2017214396A (ja) | 2008-06-17 | 2017-06-30 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2019216272A Withdrawn JP2020055829A (ja) | 2008-06-17 | 2019-11-29 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2021109909A Withdrawn JP2021165288A (ja) | 2008-06-17 | 2021-07-01 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2023145377A Withdrawn JP2023158150A (ja) | 2008-06-17 | 2023-09-07 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2025141388A Pending JP2025172854A (ja) | 2008-06-17 | 2025-08-27 | ボロン酸エステル化合物およびその医薬組成物 |
Family Applications After (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014103398A Withdrawn JP2014169317A (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103396A Active JP6110813B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103395A Active JP6010066B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2014103397A Active JP5926319B2 (ja) | 2008-06-17 | 2014-05-19 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2017128843A Withdrawn JP2017214396A (ja) | 2008-06-17 | 2017-06-30 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2019216272A Withdrawn JP2020055829A (ja) | 2008-06-17 | 2019-11-29 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2021109909A Withdrawn JP2021165288A (ja) | 2008-06-17 | 2021-07-01 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2023145377A Withdrawn JP2023158150A (ja) | 2008-06-17 | 2023-09-07 | ボロン酸エステル化合物およびその医薬組成物 |
| JP2025141388A Pending JP2025172854A (ja) | 2008-06-17 | 2025-08-27 | ボロン酸エステル化合物およびその医薬組成物 |
Country Status (39)
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7687456B2 (en) | 2005-11-09 | 2010-03-30 | Proteolix, Inc. | Compounds for enzyme inhibition |
| EP2484688B1 (en) | 2006-06-19 | 2016-06-08 | Onyx Therapeutics, Inc. | Peptide epoxyketones for proteasome inhibition |
| MX2010003732A (es) | 2007-10-04 | 2010-08-09 | Onyx Therapeutics Inc | Inhibidores de peptido cetona epoxi de proteasa cristalina y la sintesis de ceto-epoxidos de aminoacido. |
| BR122014008753A2 (pt) * | 2008-06-17 | 2015-12-29 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
| KR101023994B1 (ko) | 2008-08-28 | 2011-03-28 | 한국생산기술연구원 | 디지털 밴드용 커넥터, 리셉터클 및 커넥터 조립체 |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| PE20120059A1 (es) | 2008-10-21 | 2012-02-27 | Onyx Therapeutics Inc | Combinaciones farmaceuticas con epoxicetonas peptidicas |
| TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
| US8853147B2 (en) | 2009-11-13 | 2014-10-07 | Onyx Therapeutics, Inc. | Use of peptide epoxyketones for metastasis suppression |
| US9359398B2 (en) | 2010-03-01 | 2016-06-07 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| CN106008570A (zh) | 2010-03-31 | 2016-10-12 | 米伦纽姆医药公司 | 1-氨基-2-环丙基乙硼酸衍生物 |
| US8962572B2 (en) | 2010-10-05 | 2015-02-24 | Fresenius Kabi Usa, Llc | Bortezomib formulations |
| CN102784114B (zh) * | 2011-05-14 | 2016-03-02 | 山东新时代药业有限公司 | 一种硼替佐米冻干粉针及其制备方法 |
| MX2013015308A (es) | 2011-06-22 | 2014-05-20 | Cephalon Inc | Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso. |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US20150184246A1 (en) | 2011-11-11 | 2015-07-02 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| JP6397765B2 (ja) * | 2011-11-11 | 2018-09-26 | ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | プロテアソーム阻害剤に応答するバイオマーカー |
| US9234048B2 (en) | 2012-01-18 | 2016-01-12 | Wisconsin Alumni Research Foundation | Boronate-mediated delivery of molecules into cells |
| US9732101B2 (en) | 2012-01-18 | 2017-08-15 | Wisconsin Alumni Research Foundation | Bioreversible boronates for delivery of molecules into cells |
| CA2862492A1 (en) * | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| EP2812338A4 (en) | 2012-01-24 | 2015-09-23 | Millennium Pharm Inc | METHOD FOR THE TREATMENT OF NASOPHARYNGEAL CANCER |
| AU2013227219A1 (en) * | 2012-03-02 | 2014-10-23 | Dr. Reddy's Laboratories Limited | Pharmaceutical compositions comprising boronic acid compounds |
| CA2784240C (en) | 2012-03-27 | 2014-07-08 | Innopharma, Inc. | Stable bortezomib formulations |
| US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| ITMI20121394A1 (it) * | 2012-08-06 | 2014-02-07 | Chemi Spa | Esteri di bortezomib e loro formulazioni |
| EP3008212A4 (en) * | 2013-06-10 | 2017-05-24 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| JP6165986B2 (ja) * | 2013-08-23 | 2017-07-19 | シントン・ビー．ブイ．Ｓｙｎｔｈｏｎ Ｂ．Ｖ． | ボルテゾミブを含む医薬組成物 |
| KR20160058886A (ko) * | 2013-10-03 | 2016-05-25 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 전신 홍반성 낭창 및/또는 낭창성 신염의 예방 또는 치료 방법 |
| EP3102585B1 (en) * | 2014-02-03 | 2021-05-19 | Ohio State Innovation Foundation | Boronic acid esters and pharmaceutical formulations thereof |
| JP2015200016A (ja) * | 2014-03-31 | 2015-11-12 | 富士フイルム株式会社 | 水分解用光電極、水分解装置 |
| CN106659761A (zh) | 2014-05-20 | 2017-05-10 | 千年药物公司 | 初级癌症疗法后使用的含硼蛋白酶体抑制剂 |
| EP3808349B1 (en) | 2014-08-07 | 2022-10-05 | Mayo Foundation for Medical Education and Research | Compounds and methods for treating cancer |
| EP3212196A4 (en) | 2014-10-29 | 2018-07-11 | Wisconsin Alumni Research Foundation | Boronic acid inhibitors of hiv protease |
| EP3031811A1 (en) | 2014-12-09 | 2016-06-15 | Teva Pharmaceuticals Ltd. | Malic acid esters of bortezomib |
| MA41505A (fr) * | 2015-02-11 | 2017-12-19 | Millennium Pharm Inc | Nouvelle forme cristalline d'un inhibiteur de protéasome |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| CZ2015233A3 (cs) | 2015-04-03 | 2016-10-12 | Zentiva, K.S. | Způsob přípravy Ixazomib citrátu |
| CZ2015253A3 (cs) | 2015-04-15 | 2016-10-26 | Zentiva, K.S. | Nové formy Ixazomib citrátu |
| US10144761B2 (en) | 2015-06-19 | 2018-12-04 | Hanlin Scientific Inc. | Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis |
| CN108135916B (zh) * | 2015-06-19 | 2022-01-28 | 北京科辉智药生物科技有限责任公司 | 手性特异性含硼化合物及其在治疗癌症或淀粉样变性中的应用 |
| EP3120837A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Verfahren zur herstellung einer bortezomibester-lösung |
| EP3120836A1 (de) | 2015-07-22 | 2017-01-25 | Stada Arzneimittel Ag | Gebrauchsfertige bortezomib-lösung |
| WO2017046815A1 (en) | 2015-09-16 | 2017-03-23 | Mylan Laboratories Limited | Polymorphs of ixazomib citrate and processes for the preparation thereof |
| CN106608883A (zh) * | 2015-10-21 | 2017-05-03 | 北京大学 | 蛋白酶体抑制剂mln9708的合成方法 |
| WO2017079572A1 (en) | 2015-11-04 | 2017-05-11 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having multiple myeloma |
| CN106986884A (zh) * | 2016-01-20 | 2017-07-28 | 成都贝斯凯瑞生物科技有限公司 | 一种高效的高纯度含硼化合物制备方法 |
| CN105622658B (zh) * | 2016-03-18 | 2018-06-19 | 中国药科大学 | 非肽类蛋白酶体抑制剂、其药物组合物、制备方法和应用 |
| WO2017163190A1 (en) * | 2016-03-23 | 2017-09-28 | Dr. Reddy’S Laboratories Limited | Amorphous ixazomib citrate and solid dispersion thereof |
| CN107224569A (zh) * | 2016-03-26 | 2017-10-03 | 复旦大学 | 一种硼替佐米水溶性药用组合物及其制备方法和用途 |
| CZ2016204A3 (cs) | 2016-04-08 | 2017-11-01 | Zentiva, K.S. | Formulace Ixazomib citrátu formy 3 |
| US10604537B2 (en) | 2016-06-21 | 2020-03-31 | Teva Pharmaceuticals International Gmbh | Solid state forms of ixazomib citrate |
| JP6802899B2 (ja) * | 2016-07-25 | 2020-12-23 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． | 置換ボロン酸化合物、該化合物を含む医薬組成物およびその使用 |
| CA3032011A1 (en) * | 2016-08-04 | 2018-02-08 | Millennium Pharmaceuticals, Inc. | Combination of proteasome inhibitors and anti-cd30 antibodies |
| CN108440583B (zh) * | 2017-01-23 | 2020-12-04 | 成都奥璟生物科技有限公司 | 一种新的硼酸衍生物及其药物组合物 |
| ES3036483T3 (en) | 2017-02-28 | 2025-09-19 | Mayo Found Medical Education & Res | Combinations for use in the treatment of cancer |
| WO2018158697A1 (en) | 2017-03-03 | 2018-09-07 | Fresenius Kabi Oncology Limited | A process for the preparation of ixazomib citrate |
| WO2018173071A1 (en) * | 2017-03-20 | 2018-09-27 | Msn Laboratories Private Limited, R&D Center | Novel crystalline forms of ixazomib citrate and its process for preparation thereof |
| CN106916177B (zh) * | 2017-03-23 | 2019-04-23 | 南京陵瑞医药科技有限公司 | 一种氘代的二肽硼酸或其酯类化合物及其合成方法与用途 |
| CN108794516A (zh) * | 2017-04-26 | 2018-11-13 | 上海时莱生物技术有限公司 | 硼酸和硼酸酯类化合物及其制备方法和用途 |
| CN108794520B (zh) * | 2017-05-02 | 2020-07-24 | 北京大学 | 包括埃沙佐米在内的硼酸柠檬酸酯类化合物的合成方法 |
| US11414437B2 (en) | 2017-07-28 | 2022-08-16 | Chengdu Origin Biotechnology Limited Company | Borate compound, and synthesis method therefor and uses thereof |
| WO2019038250A1 (en) | 2017-08-24 | 2019-02-28 | Merck Patent Gmbh | Boronic acid derivatives |
| US20200199159A1 (en) | 2017-08-25 | 2020-06-25 | Synthon B.V. | Process for making ixazomib or intermediates therefor |
| US10927133B2 (en) | 2017-09-02 | 2021-02-23 | Sun Pharmaceutical Industries Limited | Process for the preparation of ixazomib citrate |
| WO2019053611A1 (en) | 2017-09-14 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | POLY THERAPY FOR THE TREATMENT OF CANCER |
| CN113603713B (zh) * | 2017-12-05 | 2024-11-12 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的硼酸酯化合物的制备方法及其晶型 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| US10118937B1 (en) | 2018-01-03 | 2018-11-06 | Scinopharm Taiwan, Ltd. | Process for preparing ixazomib citrate and intermediates therefor |
| CN110041353A (zh) * | 2018-01-16 | 2019-07-23 | 成都译山生物科技有限公司 | 一种新的硼酸水杨酸酯类衍生物及其药物组合物 |
| KR102656571B1 (ko) | 2018-03-05 | 2024-04-11 | 아르커스 바이오사이언시즈 인코포레이티드 | 아르기나아제 억제제 |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| CN110540547A (zh) * | 2018-05-28 | 2019-12-06 | 秦艳茹 | 一种肽硼酸酯类化合物的合成与用途 |
| CN112469480A (zh) | 2018-07-26 | 2021-03-09 | 默克专利股份公司 | 硼酸衍生物 |
| CN112513052B (zh) * | 2018-08-02 | 2022-12-16 | 正大天晴药业集团股份有限公司 | 氮杂环丁烷衍生物的硼酸酯 |
| CN115403603A (zh) * | 2018-09-14 | 2022-11-29 | 成都奥璟生物科技有限公司 | 一种硼酸酯类药物及其用途 |
| WO2020102646A2 (en) | 2018-11-16 | 2020-05-22 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| CN110357787A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 依沙佐米合成工艺研究 |
| US12466825B2 (en) * | 2019-11-14 | 2025-11-11 | Amgen Inc. | Synthesis of KRAS G12C inhibitor compound |
| WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
| WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
| WO2023232830A1 (en) | 2022-06-02 | 2023-12-07 | Merck Patent Gmbh | Boronic acid adducts |
| JP2025521648A (ja) | 2022-06-30 | 2025-07-10 | プリンシピア バイオファーマ インコーポレイテッド | 環状ボロン酸エステル及びその使用 |
| WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
| CN116396312A (zh) * | 2022-12-26 | 2023-07-07 | 重庆迈德凯医药有限公司 | 一种枸橼酸艾沙佐米的制备方法 |
| WO2025117822A1 (en) * | 2023-11-28 | 2025-06-05 | University Of Notre Dame Du Lac | Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs |
| CN117964650B (zh) * | 2024-03-28 | 2024-06-07 | 成都硕德药业有限公司 | 一种枸橼酸伊沙佐米的制备方法 |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US449082A (en) * | 1891-03-24 | milbeadt | ||
| US2160413A (en) | 1935-04-16 | 1939-05-30 | Schering Ag | Polyiodo derivatives of acylamino acids and their salts and a method of making the same |
| NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| JPS6197352A (ja) * | 1984-10-17 | 1986-05-15 | Dai Ichi Kogyo Seiyaku Co Ltd | 安定性に優れた組成物 |
| JPS6233170A (ja) | 1985-08-07 | 1987-02-13 | Tokuyama Soda Co Ltd | 環状ポリエ−テル化合物 |
| JPH0813759B2 (ja) | 1986-09-01 | 1996-02-14 | 富士写真フイルム株式会社 | アルコキシベンゼン誘導体の製造方法 |
| JP2512303B2 (ja) | 1987-03-20 | 1996-07-03 | 呉羽化学工業株式会社 | ２−オキサゾリン−４，５−ジオンのフエニルヒドラゾン誘導体 |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
| US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
| US5159060A (en) * | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
| MX9206628A (es) | 1991-11-22 | 1993-05-01 | Boehringer Ingelheim Pharma | Ester de prolinaboronato y metodo para su preparacion. |
| ATE149563T1 (de) * | 1992-08-14 | 1997-03-15 | Procter & Gamble | Alpha-aminoborsäurehaltige flüssige waschmittel |
| US5442100A (en) * | 1992-08-14 | 1995-08-15 | The Procter & Gamble Company | β-aminoalkyl and β-N-peptidylaminoalkyl boronic acids |
| US5935944A (en) * | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
| US5492900A (en) * | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
| US6060462A (en) * | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| FR2712602B1 (fr) | 1993-11-18 | 1996-02-09 | Centre Nat Rech Scient | Virus recombinants, préparation et utilisation en thérapie génique. |
| US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
| JP3403009B2 (ja) * | 1996-07-12 | 2003-05-06 | キヤノン株式会社 | 可動部材の変位と気泡成長を伴う液体吐出方法、該吐出方法に用いられる液体吐出ヘッド、ヘッドカートリッジ及びこれらを用いた液体吐出装置 |
| US5834487A (en) | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
| AU741802B2 (en) | 1997-02-15 | 2001-12-13 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts through inhibition of NF-kappaB |
| AU9580098A (en) | 1997-09-25 | 1999-04-12 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| CN1282242A (zh) | 1997-12-16 | 2001-01-31 | 赛福伦公司 | 多相催化蛋白酶抑制剂用作抗肿瘤剂 |
| US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
| WO2000024392A1 (en) | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | β-AMYLOID FORMATION INHIBITORS |
| US6169076B1 (en) * | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
| US6121149A (en) * | 1999-04-22 | 2000-09-19 | Advanced Micro Devices, Inc. | Optimized trench/via profile for damascene filling |
| KR100307027B1 (ko) | 1999-06-17 | 2001-11-01 | 서평원 | 액정 표시장치 및 이것을 이용한 이동 통신 단말기의 표시장치 |
| EP1196436A2 (en) | 1999-07-07 | 2002-04-17 | Bristol-Myers Squibb Pharma Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| SE0100714D0 (sv) | 2000-07-13 | 2001-02-28 | Ap Biotech Ab | Reaction vessel and method for distributing fluid in such a vessel |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| JP2002145848A (ja) * | 2000-11-10 | 2002-05-22 | Kyorin Pharmaceut Co Ltd | アルケニルアミノ酸誘導体及びその製造法 |
| EP1217000A1 (en) * | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| EP2251344B2 (en) | 2001-01-25 | 2024-04-24 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Formulation of boronic acid compounds |
| WO2002096933A1 (en) | 2001-05-30 | 2002-12-05 | Novartis Ag | 2-{[n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl]-amino}-alkylboronic acid derivatives |
| DE10131283A1 (de) | 2001-06-28 | 2003-01-09 | Philips Corp Intellectual Pty | Phased Array Antenne |
| JPWO2003033507A1 (ja) | 2001-10-12 | 2005-02-03 | 杏林製薬株式会社 | ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬 |
| JPWO2003033506A1 (ja) | 2001-10-12 | 2005-02-03 | 杏林製薬株式会社 | アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬 |
| AU2003219652A1 (en) | 2002-01-08 | 2003-07-30 | Eisai Co. Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
| WO2003105860A1 (en) | 2002-06-14 | 2003-12-24 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
| US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
| DE60305113T2 (de) | 2002-09-09 | 2006-12-07 | Trigen Ltd. | Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7576206B2 (en) * | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CN1867572B (zh) * | 2003-08-14 | 2012-03-28 | 赛福伦公司 | 蛋白酶体抑制剂及其使用方法 |
| GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
| PL4008721T3 (pl) | 2004-03-30 | 2024-05-13 | Millennium Pharmaceuticals, Inc. | Synteza związków estrów i kwasów boronowych |
| SG185963A1 (en) | 2004-05-10 | 2012-12-28 | Onyx Therapeutics Inc | Compounds for enzyme inhibition |
| WO2006008660A2 (en) | 2004-07-20 | 2006-01-26 | Affinium Pharmaceuticals, Inc. | Streptococcus pneumoniae enoyl- (acyl-carrier-protein) reductase (fabk) |
| TW200618820A (en) | 2004-11-05 | 2006-06-16 | Alza Corp | Liposome formulations of boronic acid compounds |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CN101120006A (zh) * | 2005-02-11 | 2008-02-06 | 赛福伦公司 | 蛋白酶体抑制剂及其使用方法 |
| EP1874297A4 (en) | 2005-04-29 | 2009-04-22 | Kosan Biosciences Inc | METHOD OF TREATING MULTIPLE MYELOMES USING 17AGENE OR 17-AG OR A PRODRUG OR ALL IN COMBINATION WITH A PROTEASOMIC INHIBITOR |
| KR20080030079A (ko) | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
| KR20080074220A (ko) * | 2005-12-08 | 2008-08-12 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 키나아제 억제 활성을 갖는 비시클릭 화합물 |
| JP2009524681A (ja) | 2006-01-27 | 2009-07-02 | フェノミックス コーポレーション | Ｃ型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用 |
| EP1988083B1 (en) | 2006-02-03 | 2014-04-02 | Taisho Pharmaceutical Co., Ltd. | Triazole derivative |
| CL2007002499A1 (es) * | 2006-08-30 | 2008-03-14 | Phenomix Corp | Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes. |
| WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| GEP20125599B (en) | 2007-08-06 | 2012-08-10 | Millennium Pharm Inc | Proteasome inhibitors |
| ITMI20072397A1 (it) | 2007-12-20 | 2009-06-21 | Gambro Lundia Ab | Apparecchiatura medicale per il trattamento extracorporeo |
| BR122014008753A2 (pt) * | 2008-06-17 | 2015-12-29 | Millennium Pharm Inc | compostos de éster boronato e composições farmacêuticas dos mesmos |
| AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
| CN106008570A (zh) | 2010-03-31 | 2016-10-12 | 米伦纽姆医药公司 | 1-氨基-2-环丙基乙硼酸衍生物 |
| BR112013026094A2 (pt) | 2011-04-29 | 2016-12-27 | Ericsson Telefon Ab L M | controle descentralizado de redução de interferência em um sistema de comunicação sem fio |
| JP5724951B2 (ja) | 2012-06-11 | 2015-05-27 | 日立金属株式会社 | ネットワーク管理装置 |
| JP6357023B2 (ja) | 2014-06-06 | 2018-07-11 | 任天堂株式会社 | 情報処理プログラム、情報処理装置、情報処理装置の制御方法および情報処理システム |
-
2009
- 2009-06-16 BR BR122014008753A patent/BR122014008753A2/pt not_active Application Discontinuation
- 2009-06-16 KR KR1020147019858A patent/KR101704694B1/ko active Active
- 2009-06-16 CN CN201310349618.4A patent/CN103497210A/zh active Pending
- 2009-06-16 CN CN201710292950.XA patent/CN107253966A/zh active Pending
- 2009-06-16 RS RS20150366A patent/RS54020B2/sr unknown
- 2009-06-16 FI FIEP09767050.9T patent/FI2318419T4/fi active
- 2009-06-16 MX MX2017014406A patent/MX358222B/es unknown
- 2009-06-16 CA CA2727862A patent/CA2727862C/en active Active
- 2009-06-16 UA UAA201403777A patent/UA115131C2/uk unknown
- 2009-06-16 NZ NZ624122A patent/NZ624122A/en unknown
- 2009-06-16 WO PCT/US2009/003602 patent/WO2009154737A1/en not_active Ceased
- 2009-06-16 SG SG10201701524XA patent/SG10201701524XA/en unknown
- 2009-06-16 NZ NZ624123A patent/NZ624123A/en unknown
- 2009-06-16 CN CN2013103491814A patent/CN103467565A/zh active Pending
- 2009-06-16 CA CA2921946A patent/CA2921946C/en active Active
- 2009-06-16 NZ NZ624121A patent/NZ624121A/en not_active IP Right Cessation
- 2009-06-16 CN CN2013103488135A patent/CN103435638A/zh active Pending
- 2009-06-16 EA EA201500430A patent/EA030685B1/ru not_active IP Right Cessation
- 2009-06-16 EP EP09767050.9A patent/EP2318419B2/en active Active
- 2009-06-16 EP EP13191414.5A patent/EP2730581B1/en not_active Revoked
- 2009-06-16 MY MYPI2014003632A patent/MY171021A/en unknown
- 2009-06-16 KR KR1020117001181A patent/KR101691093B1/ko active Active
- 2009-06-16 DK DK09767050.9T patent/DK2318419T4/da active
- 2009-06-16 PT PT131914145T patent/PT2730581T/pt unknown
- 2009-06-16 KR KR1020177013867A patent/KR101860743B1/ko active Active
- 2009-06-16 CN CN201710333805.1A patent/CN107253975B/zh active Active
- 2009-06-16 CN CN201710312608.1A patent/CN107266482A/zh active Pending
- 2009-06-16 KR KR1020147019854A patent/KR101690571B1/ko not_active Expired - Fee Related
- 2009-06-16 BR BR122014008750A patent/BR122014008750A2/pt not_active Application Discontinuation
- 2009-06-16 BR BRPI0915300A patent/BRPI0915300C1/pt active IP Right Grant
- 2009-06-16 EP EP19150417.4A patent/EP3536693A1/en active Pending
- 2009-06-16 EP EP13191409.5A patent/EP2730579A1/en not_active Withdrawn
- 2009-06-16 EA EA201500432A patent/EA201500432A1/ru unknown
- 2009-06-16 ES ES09767050T patent/ES2541467T5/es active Active
- 2009-06-16 MX MX2013010325A patent/MX349769B/es unknown
- 2009-06-16 US US12/485,344 patent/US20090325903A1/en not_active Abandoned
- 2009-06-16 SI SI200931201T patent/SI2318419T2/sl unknown
- 2009-06-16 MX MX2010013642A patent/MX2010013642A/es active IP Right Grant
- 2009-06-16 JP JP2011514598A patent/JP5566380B2/ja active Active
- 2009-06-16 GE GEAP200912730A patent/GEP201706703B/en unknown
- 2009-06-16 MX MX2013010326A patent/MX340186B/es unknown
- 2009-06-16 DK DK13191414.5T patent/DK2730581T3/en active
- 2009-06-16 HR HRP20150592TT patent/HRP20150592T4/hr unknown
- 2009-06-16 SG SG2013069851A patent/SG194349A1/en unknown
- 2009-06-16 CN CN201310349472.3A patent/CN103497232A/zh active Pending
- 2009-06-16 CN CN201710264997.5A patent/CN107266480A/zh active Pending
- 2009-06-16 PL PL09767050T patent/PL2318419T3/pl unknown
- 2009-06-16 EP EP20130191412 patent/EP2730580A1/en not_active Withdrawn
- 2009-06-16 KR KR1020147019860A patent/KR101741142B1/ko active Active
- 2009-06-16 EA EA201500431A patent/EA201500431A1/ru unknown
- 2009-06-16 MY MYPI2010005940A patent/MY155592A/en unknown
- 2009-06-16 NZ NZ603236A patent/NZ603236A/en unknown
- 2009-06-16 CN CN201310349247XA patent/CN103450241A/zh active Pending
- 2009-06-16 ES ES13191414.5T patent/ES2585114T3/es active Active
- 2009-06-16 CN CN2009801230135A patent/CN102066386A/zh active Pending
- 2009-06-16 EP EP13191413.7A patent/EP2733147A1/en not_active Withdrawn
- 2009-06-16 EA EA201170036A patent/EA027346B1/ru not_active IP Right Cessation
- 2009-06-16 GE GEAP2009012060 patent/GEP20135847B/en unknown
- 2009-06-16 AU AU2009260778A patent/AU2009260778B2/en active Active
- 2009-06-16 PT PT97670509T patent/PT2318419E/pt unknown
- 2009-06-16 BR BR122014008754A patent/BR122014008754A2/pt not_active Application Discontinuation
- 2009-06-17 TW TW098120303A patent/TWI498333B/zh active
- 2009-06-17 TW TW103118480A patent/TWI543985B/zh active
- 2009-06-17 PE PE2014000150A patent/PE20141064A1/es not_active Application Discontinuation
- 2009-06-17 AR ARP090102187A patent/AR072162A1/es active IP Right Grant
- 2009-06-17 PE PE2009000877A patent/PE20100256A1/es active IP Right Grant
- 2009-06-17 PE PE2014000152A patent/PE20141076A1/es not_active Application Discontinuation
- 2009-06-17 PE PE2014000153A patent/PE20141065A1/es not_active Application Discontinuation
- 2009-06-17 PE PE2014000151A patent/PE20141078A1/es not_active Application Discontinuation
- 2009-06-17 TW TW103118482A patent/TWI542351B/zh not_active IP Right Cessation
-
2010
- 2010-12-10 DO DO2010000384A patent/DOP2010000384A/es unknown
- 2010-12-16 CR CR11850A patent/CR11850A/es unknown
- 2010-12-16 IL IL210056A patent/IL210056B/en active IP Right Grant
- 2010-12-17 CL CL2010001475A patent/CL2010001475A1/es unknown
- 2010-12-21 ZA ZA2010/09177A patent/ZA201009177B/en unknown
- 2010-12-23 CO CO10161489A patent/CO6321289A2/es active IP Right Grant
-
2011
- 2011-01-13 MA MA33514A patent/MA32471B1/fr unknown
- 2011-01-17 EC EC2011010763A patent/ECSP11010763A/es unknown
- 2011-11-07 HK HK14111508.6A patent/HK1198252A1/en unknown
- 2011-11-07 HK HK14111509.5A patent/HK1198253A1/en unknown
- 2011-11-07 HK HK14111716.4A patent/HK1198254A1/en unknown
- 2011-12-20 ZA ZA2011/09368A patent/ZA201109368B/en unknown
-
2012
- 2012-11-02 US US13/667,164 patent/US8859504B2/en active Active
-
2013
- 2013-06-25 ZA ZA2013/04728A patent/ZA201304728B/en unknown
-
2014
- 2014-05-14 EC ECSP14010763 patent/ECSP14010763A/es unknown
- 2014-05-19 JP JP2014103398A patent/JP2014169317A/ja not_active Withdrawn
- 2014-05-19 JP JP2014103396A patent/JP6110813B2/ja active Active
- 2014-05-19 JP JP2014103395A patent/JP6010066B2/ja active Active
- 2014-05-19 JP JP2014103397A patent/JP5926319B2/ja active Active
- 2014-08-01 US US14/449,328 patent/US9175018B2/en active Active
- 2014-08-01 US US14/449,275 patent/US9175017B2/en active Active
- 2014-08-25 IL IL234285A patent/IL234285B/en active IP Right Grant
- 2014-08-25 IL IL234286A patent/IL234286A/en active IP Right Grant
-
2015
- 2015-05-27 PH PH12015501192A patent/PH12015501192A1/en unknown
- 2015-05-27 PH PH12015501193A patent/PH12015501193A1/en unknown
- 2015-05-27 PH PH12015501191A patent/PH12015501191B1/en unknown
- 2015-06-08 ZA ZA2015/04133A patent/ZA201504133B/en unknown
- 2015-06-16 CY CY20151100519T patent/CY1116435T1/el unknown
- 2015-10-12 US US14/880,776 patent/US20160031913A1/en not_active Abandoned
-
2016
- 2016-01-08 CR CR20160014A patent/CR20160014A/es unknown
- 2016-01-08 CR CR20160015A patent/CR20160015A/es unknown
-
2017
- 2017-05-04 NO NO2017016C patent/NO2017016I1/no unknown
- 2017-06-30 JP JP2017128843A patent/JP2017214396A/ja not_active Withdrawn
- 2017-09-12 US US15/701,791 patent/US20180002350A1/en not_active Abandoned
-
2018
- 2018-03-22 US US15/928,139 patent/US20180208609A1/en not_active Abandoned
- 2018-03-27 HK HK18104204.4A patent/HK1244811A1/zh unknown
- 2018-03-27 HK HK18104201.7A patent/HK1244809A1/zh unknown
- 2018-03-27 HK HK18104202.6A patent/HK1244827A1/zh unknown
- 2018-03-27 HK HK18104203.5A patent/HK1244810A1/zh unknown
- 2018-10-18 US US16/163,694 patent/US20190048028A1/en not_active Abandoned
-
2019
- 2019-01-29 US US16/260,596 patent/US10526351B2/en active Active
- 2019-05-08 US US16/406,159 patent/US20190263839A1/en not_active Abandoned
- 2019-09-13 US US16/570,065 patent/US10604538B2/en active Active
- 2019-11-29 JP JP2019216272A patent/JP2020055829A/ja not_active Withdrawn
-
2020
- 2020-02-12 US US16/788,824 patent/US20200181176A1/en not_active Abandoned
- 2020-04-24 US US16/857,227 patent/US11485746B2/en active Active
- 2020-09-01 US US17/009,199 patent/US20200392164A1/en not_active Abandoned
-
2021
- 2021-03-11 US US17/198,442 patent/US20210198289A1/en not_active Abandoned
- 2021-07-01 JP JP2021109909A patent/JP2021165288A/ja not_active Withdrawn
- 2021-09-23 US US17/483,724 patent/US20220009948A1/en not_active Abandoned
-
2023
- 2023-05-03 US US18/311,290 patent/US20230265111A1/en not_active Abandoned
- 2023-09-07 JP JP2023145377A patent/JP2023158150A/ja not_active Withdrawn
-
2025
- 2025-08-27 JP JP2025141388A patent/JP2025172854A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524903A5 (enExample) | ||
| HRP20150592T1 (hr) | Organoborni esterski spojevi i njihove farmaceutske kompozicije | |
| JP2010090149A5 (enExample) | ||
| TWI657826B (zh) | Complex of angiotensin II receptor antagonist metabolite and NEP inhibitor and preparation method thereof | |
| JP2013519632A5 (enExample) | ||
| JP7137850B2 (ja) | バレニクリンまたはその薬学的に許容可能な塩の包接複合体を含む口腔投与用製剤 | |
| JP2018035160A5 (enExample) | ||
| JP2008525445A5 (enExample) | ||
| JP2012502037A5 (enExample) | ||
| JP2012067115A5 (enExample) | ||
| JP6483674B2 (ja) | ５−ブロモ−２−（α−ヒドロキシペンチル）安息香酸ナトリウム塩の複数の異なる結晶型及びそれらの調製方法 | |
| JP2009521269A5 (enExample) | ||
| TW201720444A (zh) | 含有2-{4-[n-(5,6-二苯基吡 -2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| JP2012510985A5 (enExample) | ||
| CN103228618A (zh) | 新化合物及其医药用途 | |
| WO2013139195A1 (zh) | 石杉碱甲多晶型体、其制备方法、包含所述多晶型体的药物组合物及其用途 | |
| JP2006500367A (ja) | ブチルフタリドとシクロデキストリンまたはその誘導体との包接複合体、それらの調製のためのプロセスおよびその使用 | |
| JP2011506492A5 (enExample) | ||
| JP2009040767A5 (enExample) | ||
| JP2009502777A5 (enExample) | ||
| JP2008542386A5 (enExample) | ||
| CN104083383B (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物在制备抗急性肾衰药物中的应用 | |
| RU2004124840A (ru) | Твердые соли бензазепиновых соединений и их применение при получении фармацевтических соединений | |
| RU2593260C2 (ru) | Производное бутилфталида, способ его получения и применение | |
| JP5461084B2 (ja) | 崩壊遅延が抑制されたパロキセチン塩酸塩水和物の経口投与用医薬組成物 |